StockWatch
·
Biotechnology: Pharmaceutical Preparations
ClarificationNov 20, 2026, 04:33 PM

Abivax Responds to Short Seller Report, Denies Inaccuracies

AI Summary

Abivax SA has issued a statement addressing a report published by Scorpion Capital, asserting that the report contains numerous factually inaccurate and misleading statements. The company is reviewing the report and will provide further updates. Abivax firmly stands behind its clinical development program, including Phase 3 ABTECT trial results and clinical data, which will support its U.S. FDA NDA filing by year-end. Scorpion Capital disclosed a short position in Abivax, indicating a direct financial interest in a decline of the company's share price.

Key Highlights

  • Abivax is reviewing a report published by Scorpion Capital.
  • Abivax states the Scorpion Capital report contains numerous factually inaccurate and misleading statements.
  • Abivax stands behind the integrity of its clinical development program and Phase 3 ABTECT trial results.
  • Abivax plans to support its U.S. FDA NDA filing by the end of the year with current clinical data.
  • Scorpion Capital disclosed a short position in Abivax and an intention to cover a portion of it upon report publication.